Ventyx Biosciences to be Acquired by Eli Lilly for $14.00 Per Share in Cash

summarizeSummary

Ventyx Biosciences, Inc. has entered into a definitive agreement to be acquired by Eli Lilly and Company for $14.00 per share in cash, representing a significant corporate event for the company.

check_boxKey Events

• Definitive Merger Agreement

  Ventyx Biosciences, Inc. has entered into an Agreement and Plan of Merger with Eli Lilly and Company, under which Eli Lilly will acquire Ventyx Biosciences.

• Cash Acquisition Price

  Each share of Ventyx Biosciences common stock will be converted into the right to receive $14.00 per share in cash, without interest, at the effective time of the merger.

• Shareholder Support

  Raju Mohan, a beneficial owner of 6.0% of the company's common stock (including options), has entered into a voting and support agreement, committing to vote in favor of the merger.

auto_awesomeAnalysis

Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company. This is a thesis-altering event, providing a clear cash exit for shareholders at $14.00 per share. The reporting person, Raju Mohan, a significant beneficial owner, has signed a voting and support agreement, which increases the certainty of the merger's completion. Investors should consider the fixed cash value against any potential future upside as a standalone company.